Compare IRON & CENT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRON | CENT |
|---|---|---|
| Founded | 2017 | 1955 |
| Country | United States | United States |
| Employees | N/A | 6000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2020 | N/A |
| Metric | IRON | CENT |
|---|---|---|
| Price | $69.83 | $43.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | ★ $103.18 | $50.00 |
| AVG Volume (30 Days) | ★ 384.6K | 59.0K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.60 |
| Revenue Next Year | $283.52 | $2.04 |
| P/E Ratio | ★ N/A | $15.73 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.00 | $28.77 |
| 52 Week High | $99.50 | $43.27 |
| Indicator | IRON | CENT |
|---|---|---|
| Relative Strength Index (RSI) | 54.12 | 72.66 |
| Support Level | $64.48 | $37.06 |
| Resistance Level | $71.85 | N/A |
| Average True Range (ATR) | 3.26 | 0.92 |
| MACD | 0.04 | 0.40 |
| Stochastic Oscillator | 64.61 | 88.93 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.